New Zealand markets close in 2 hours 17 minutes

Zhejiang Cheng Yi Pharmaceutical Co., Ltd. (603811.SS)

Shanghai - Shanghai Delayed price. Currency in CNY
Add to watchlist
8.000.00 (0.00%)
As of 10:28AM CST. Market open.
Currency in CNY

Valuation measures4

Market cap (intra-day) 2.62B
Enterprise value 2.80B
Trailing P/E 16.67
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)3.84
Price/book (mrq)2.14
Enterprise value/revenue 4.13
Enterprise value/EBITDA 15.12

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-38.46%
S&P500 52-week change 329.31%
52-week high 313.86
52-week low 35.78
50-day moving average 38.04
200-day moving average 39.80

Share statistics

Avg vol (3-month) 34.1M
Avg vol (10-day) 33.39M
Shares outstanding 5327.3M
Implied shares outstanding 6335.08M
Float 8192.35M
% held by insiders 138.76%
% held by institutions 117.37%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.25
Forward annual dividend yield 43.13%
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 41.64
Payout ratio 452.08%
Dividend date 3N/A
Ex-dividend date 408 Jun 2023
Last split factor 21.4:1
Last split date 308 Jun 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 23.02%
Operating margin (ttm)19.47%

Management effectiveness

Return on assets (ttm)4.68%
Return on equity (ttm)13.15%

Income statement

Revenue (ttm)676.85M
Revenue per share (ttm)2.09
Quarterly revenue growth (yoy)3.50%
Gross profit (ttm)N/A
EBITDA 219.74M
Net income avi to common (ttm)155.83M
Diluted EPS (ttm)0.48
Quarterly earnings growth (yoy)-17.80%

Balance sheet

Total cash (mrq)251.96M
Total cash per share (mrq)0.77
Total debt (mrq)429.48M
Total debt/equity (mrq)34.94%
Current ratio (mrq)1.68
Book value per share (mrq)3.75

Cash flow statement

Operating cash flow (ttm)155.56M
Levered free cash flow (ttm)88.41M